Global Blood Glucose Monitoring Market Size, Share, Forecast Report, 2020-2027

Blood glucose monitoring is the process of testing the diabetes level in the blood. It helps to recognize the glucose level of blood within the specified target range. The blood glucose monitoring devices provide useful insight to manage diabetes. It helps to track the progress of treatment goal as well as observe the effect of medication on blood sugar level and understand how ailment effect the glucose level in blood.

Various blood glucose monitoring devices are present in the market, which is known as blood glucose meter. These devices are designed to apply to the different type of diabetes such as Type 1, Type 2, and gestational diabetes. The blood glucose monitoring devices market growth is majorly attributed to the increasing prevalence of diabetes, developing technology for monitoring and diagnosis of diabetes, early detection of diabetes, and increasing demand for continuous glucose monitoring devices.
According to the Diabetes prevalence figures suggested by the Australian Bureau of Statistics, more than 5.1% of the Australian population was diagnosed with diabetes in 2016. However, as per the Centers for Disease Control and Prevention (CDC), in 2015, around 30.3 million of Americans were suffering from diabetes that is 9.4% of the total U.S. population. According to IDF, in 2017, total 8.8% of adults aged 20-79 years have diabetes.
Segmentations

Global blood glucose monitoring devices market is segmented on the basis of product type, application, and end user

On the basis of the product type, it is segmented into invasive glucose monitoring devices, continuous glucose monitoring devices (CGM), flash glucose monitoring devices, and others.

On the basis of the application, it is segmented into type 1 diabetes, type 2 diabetes, and others.

On the basis of the end user, it is segmented into diagnostic centers, hospitals, clinics, research centers, and home care diagnostics.
Key Players

Some of key the players in the market are Abbott Laboratories (U.S.), Arkay, Inc. (U.S.), Bayer Healthcare AG (Germany), F. Hoffmann-La Roche Ltd (Switzerland), Goldsite Diagnostics Inc., GlySure Ltd (U.K), Sphere Medical Holding plc. (U.K), Dexcom, Inc. (U.S.), and LifeScan, Inc. (U.S.).